Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
12/2003
12/09/2003US6660735 Urea substituted imidazoquinoline ethers
12/09/2003US6660732 Ureas and thioureas inhibit production of cytokines
12/09/2003US6660723 Activating primate gamma delta lymphocytes
12/09/2003US6660722 Therapeutical treatments
12/09/2003US6660721 Anti-HCV nucleoside derivatives
12/09/2003US6660718 3-modified leucomycin derivatives
12/09/2003US6660521 Use of trans-activation and CIS-activation to increase the persistence of a transgene in an at least E4-deficient adenovirus
12/09/2003US6660513 Porcine reproductive and respiratory syndrome vaccine, based on isolate JA-142
12/09/2003US6660512 Human lysozyme gene, it's encoded polypeptide and the method of preparing them
12/09/2003US6660482 Diagnosing sepsis by contacting a bodily fluid with a ligand which binds to an inter-alpha trypsin inhibitor (ITI) polypeptide to form an ITI-ligand complex and detecting the complex.
12/09/2003US6660299 Treating a bacterial infection in a human by administering a specified high dosage of amoxycillin over given time
12/09/2003US6660289 Disinfecting composition based on H2O2, acids and metal ions
12/09/2003US6660275 Amplification nucleic acids
12/09/2003US6660274 Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
12/09/2003US6660270 Immunization of dairy cattle with chimeric GapC protein against Streptococcus infection
12/09/2003US6660269 Canine tropical pancytopenia;
12/09/2003US6660268 Proteasome regulation of NF-KB activity
12/09/2003US6660264 Treatment of intracellular infection
12/09/2003US6660261 Bordetella strain expressing the FHA hybrid, liposomes and vaccines
12/09/2003US6660249 Inhalable dry powder aztreonam for treatment and prevention of pulmonary bacterial infections
12/09/2003CA2301649C Burn treatment composition
12/09/2003CA2229955C Papilloma virus capsomere vaccine formulations and methods of use
12/09/2003CA2111580C Immunogen composites with noted anticytokin effect, process of preparation, pharmaceutical compositions and kits containing them
12/09/2003CA2106492C Herpes simplex vaccine comprising hsv glycoprotein gd and 3 deacylated monophosphoryl lipid a
12/09/2003CA2104776C Thalidomide derivatives, method of manufacture and use thereof in medicaments
12/04/2003WO2003100427A1 Method for identification of a ligand whereby receptor residence time is measured
12/04/2003WO2003100045A1 Plant thymidine kinases and their use
12/04/2003WO2003100040A1 A method for generating antigen-presenting cells
12/04/2003WO2003100036A2 Novel antiretroviral sulpholipids extracted from spirulinae, method for obtaining same, compositions containing same and use thereof as inhibitors of the hiv virus reverse transcriptase
12/04/2003WO2003099858A1 Cross-linked glycopeptide-cephalosporin antibiotics
12/04/2003WO2003099851A2 Methods and compositions for inhibiting hiv replication
12/04/2003WO2003099845A2 Fas peptide mimetics and uses thereof
12/04/2003WO2003099839A1 Modulators and inhibitors of fibroblast growth factor receptor 5_polypeptides and gene expression thereof.
12/04/2003WO2003099824A1 R-enantiomers of pyranoindole derivatives against hepatitis c
12/04/2003WO2003099821A1 Azepinoindole and pyridoindole derivatives as pharmaceutical agents
12/04/2003WO2003099820A1 Pyrazolo-pyrimidine aniline compounds
12/04/2003WO2003099815A1 Crystalline fluoroquinolone arginine salt form
12/04/2003WO2003099811A1 Kinase inhibitors
12/04/2003WO2003099808A1 Substituted heterocyclic compounds and methods of use
12/04/2003WO2003099805A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
12/04/2003WO2003099801A1 Novel anti-infectives
12/04/2003WO2003099796A1 Protein kinase inhibitors
12/04/2003WO2003099752A1 Gingerol analogues and use thereof
12/04/2003WO2003099326A1 Novel uses of parapoxvirus preparations
12/04/2003WO2003099316A1 Heterocyclicsulfonamide hepatitis c virus inhibitors
12/04/2003WO2003099309A1 Active fraction having anti-cancer and anti-metastasis isolated from acanthopanax species and fruits
12/04/2003WO2003099308A1 Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng
12/04/2003WO2003099304A1 Composition against periodontal bacteria and foods, drinks and mouth washers against periodontal bacteria containing the composition
12/04/2003WO2003099303A1 Anti-helicobacter activity of celery seed extract
12/04/2003WO2003099302A1 A terpene-based composition of substances, a method for its preparation and a method for its dispersal into the atmosphere
12/04/2003WO2003099294A1 Drugs improved in tissue selectivity
12/04/2003WO2003099275A1 Method for the use of pyranoindole derivatives to treat infection with hepatitis c virus
12/04/2003WO2003099274A1 Hepatitis c virus inhibitors
12/04/2003WO2003099256A2 FREE-FLOWING, POWDERY COMPOSITION CONTAINING α-LIPONIC ACID (DERIVATIVES)
12/04/2003WO2003099226A2 Antibody peg positional isomers, compositions comprising same, and use thereof
12/04/2003WO2003099221A2 Methods for using jnk inhibitors for treating or preventing disease-related wasting
12/04/2003WO2003099217A2 Methods of treating bacterial infections and diseases associated therewith
12/04/2003WO2003099201A2 Compositions and methods of use for a fibroblast growth factor
12/04/2003WO2003099195A2 Immunomodulatory compounds and methods of use thereof
12/04/2003WO2003099192A2 Bis-aromatic alkanols
12/04/2003WO2003099110A2 Herbs and herbal combinations useful for the treatment of microbial infections
12/04/2003WO2003099011A1 Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
12/04/2003WO2003099006A1 Disinfectant with activity against hepatitis b virus
12/04/2003WO2003086309A3 NF-κB INHIBITORS
12/04/2003WO2003082881A3 Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors
12/04/2003WO2003082196A3 Combination therapy using trefoil peptides
12/04/2003WO2003077829A3 Process for preparation of a pharmaceutical composition containing acid labile compounds
12/04/2003WO2003070981A3 Seequences specifically deleted mycobacterium tuberculosis genome and their use in diagnostics and as vaccines
12/04/2003WO2003068790A3 Macrolide antibacterial compounds
12/04/2003WO2003068201A3 High affinity antibody having a tcr-like specificity and use in detection and treatment
12/04/2003WO2003066810A3 Recombinant bovine immunodeficiency virus based gene transfer system
12/04/2003WO2003064596A3 Desaturase genes, enzymes encoded thereby, and uses thereof
12/04/2003WO2003059878A3 Thieno (3, 2-b) pyridones as antiviral compounds
12/04/2003WO2003059263A3 Inorganic nanoparticles to modify the viscosity and physical properties of ophthalmic and otic compositions.
12/04/2003WO2003054017A3 Mono-and dual chemokine/cytokine constructs
12/04/2003WO2003050499A3 Use of a labeled ligand having human cd4 specificity
12/04/2003WO2003039523A3 OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
12/04/2003WO2003032920A3 Oligonucleotide modulation of cell adhesion
12/04/2003WO2003030878A3 Galenic microparticulate oral formulation
12/04/2003WO2003028736A3 Pharmaceutical preparations comprising alkyl phosphocholine compounds in liposomes which may be sterile-filtered or heat-sterilised
12/04/2003WO2003027085A3 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
12/04/2003WO2003025003A3 Hiv-gag codon-optimised dna vaccines
12/04/2003WO2003022879A3 Peptides mimicking a cryptic epitope of gp41 hiv-1 and antibodies directed against them
12/04/2003WO2003022217A3 Treatment of excessive radiation (e.g. sunburn) exposure
12/04/2003WO2003015748A3 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
12/04/2003WO2003010138A3 Piperidine derivatives as antibacterial agents
12/04/2003WO2003009704A3 Enteral compositions for the prevention and/or treatment of sepsis
12/04/2003WO2003008579A3 Polynucleotides expressed in dendritic cells and polypeptides encoded thereby
12/04/2003WO2003006996A3 Natural ligand of gpcr chemr23 and uses thereof
12/04/2003WO2002102310A3 Proteins associated with cell growth, differentiation, and death
12/04/2003WO2002096936A3 Daptomycin and related analogs in crystalline form, their preparation and use
12/04/2003WO2002094796A3 Benzo[g]quinoxaline derivatives as effective compounds against infectious diseases
12/04/2003WO2002086090A3 Identification of essential genes of aspegillus fumigatus and methods of use
12/04/2003WO2002081519A9 Ifn-thy fusion protein,dna coding therefore,its preparation and application
12/04/2003WO2002080965A3 Vaccine composition
12/04/2003WO2002073208A3 Anti-epileptogenic agents
12/04/2003WO2002068635A3 Methods of inhibiting expression of a target gene in mammalian cells
12/04/2003WO2002068397A8 Diaminoquinazoline esters for use as dihydrofolate reductade inhibitors
12/04/2003WO2002055080A3 Method of immunomodulation using thione-forming disulfides
12/04/2003WO2002036806A9 Expression vectors able to elicit improved immune response and methods of using same
1 ... 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 ... 1798